Narrowband vs Broadband UVB for Adult Eczema: The 2026 Trial
Doctor’s Notes · Eczema Research · Updated November 9, 2026
Ultraviolet B phototherapy is not one uniform treatment. A 2026 randomized trial directly compared full-body broadband UVB with narrowband UVB in adults whose moderate-to-severe atopic dermatitis had not responded adequately to topical corticosteroids. The useful result is not that one light source “cured” eczema. Both groups improved over 12 weeks, while the uncertainty around the between-group difference remained substantial and withdrawals for adverse events occurred only in the broadband group.
What the randomized trial actually tested
The Canadian study randomized 69 adults: 34 to broadband UVB and 35 to narrowband UVB. The modified intention-to-treat analysis included 32 people who received at least one broadband treatment and 34 who received at least one narrowband treatment. Participants continued concomitant topical therapy, so the study did not isolate light as a stand-alone intervention. Participants were blinded to the assigned light type, but treating and assessing clinicians were not.
| Measure | Broadband UVB | Narrowband UVB |
|---|---|---|
| Randomized | 34 adults | 35 adults |
| Received at least one treatment | 32 | 34 |
| Mean EASI change | −8.1 (95% credible interval −12.1 to −4.1) | −8.9 (95% credible interval −13.0 to −4.9) |
| Adjusted difference between groups | −0.7 (95% credible interval −5.6 to 4.1) | |
| Adverse-event withdrawals | 4 | 0 |
The adjusted difference crossed zero by a wide margin. The investigators also found no significant between-group differences in validated investigator assessment, patient-oriented eczema measure, peak itch rating, quality of life or RECAP. That pattern supports the authors’ conclusion that the two approaches were similarly effective in this study, not a claim that they were formally equivalent in every population or schedule.
Why the tolerability finding matters
Four people left the broadband arm because of adverse events, compared with none in the narrowband arm. This is clinically relevant, but the trial was small. It cannot precisely estimate uncommon harms or long-term cancer risk, and it cannot determine whether every clinic should use the same dose escalation, equipment or maintenance plan. Treatment choice still depends on access, skin type, prior therapy, medications and clinician supervision.
The trial enrolled adults with moderate-to-severe disease treated in hospital-based phototherapy units. It did not study children, mild facial eczema, tanning beds, sunlight or unsupervised home devices. A controlled UVB cabinet is not interchangeable with a cosmetic LED mask. For a focused look at a different light device, read our 308-nm excimer-light study analysis.
Questions to bring to a phototherapy appointment
- Which wavelength and dosing protocol does the clinic use?
- How will topical medicines and moisturizers be timed around each session?
- What should prompt a dose adjustment or missed treatment?
- How will eyes, face and other sensitive sites be protected?
- What cumulative-exposure record will be kept?
Practical burden matters too. Travel, changing clothes, treatment frequency and work schedules can determine whether a theoretically useful plan is realistic. Our guide to fitting phototherapy around work helps organize those questions, while the UVB and skin-cancer evidence review explains why long-term risk cannot be reduced to one reassuring or alarming number.
Where moisturizer fits—and where it does not
Dr. Arsy Hydration Recovery Moisturizer #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It is not a phototherapy drug and the UVB trial did not test #003. If a clinic recommends moisturizing during a phototherapy course, ask exactly when to apply it, because products placed on skin before light exposure can affect a clinic’s protocol.
Do not infer from this trial that home light, sunshine or tanning can reproduce a medical phototherapy result. The useful conclusion is narrower: among the adults who received treatment in this 12-week study, average outcomes were similar across the two UVB groups, and narrowband UVB was better tolerated by the withdrawal measure.
Sources
- Drucker et al. Narrowband versus broadband UVB for adults with moderate-to-severe atopic dermatitis (2026 randomized trial)
- ClinicalTrials.gov: NCT04818138
General education from the Dr. Arsy Editorial Team. Individual diagnosis and treatment require a qualified clinician. #003 is a cosmetic moisturizer; it does not treat or cure eczema. Header image is an AI-generated editorial illustration of a fictional adult with nonspecific dry skin, not a patient, diagnosis, before/after image or #003 result.